New drug aims to ease severe schizophrenia symptoms in hospitalized patients
NCT ID NCT07105098
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 27 times
Summary
This study tests a new medicine called NBI-1117568 to see if it can improve schizophrenia symptoms better than a placebo. About 284 adults with schizophrenia who need hospital care will take part. The main goal is to measure changes in symptoms like hallucinations and delusions after 5 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGCulver City, California, 90230, United States
-
Neurocrine Clinical Site
RECRUITINGGarden Grove, California, 92845, United States
-
Neurocrine Clinical Site
RECRUITINGRiverside, California, 92506, United States
-
Neurocrine Clinical Site
RECRUITINGAtlanta, Georgia, 30328, United States
-
Neurocrine Clinical Site
RECRUITINGNorth Canton, Ohio, 44720, United States
-
Neurocrine Clinical Site
RECRUITINGSliven, 8800, Bulgaria
-
Neurocrine Clinical Site
WITHDRAWNVeliko Tarnovo, 5047, Bulgaria
-
Neurocrine Clinical Site
RECRUITINGVratsa, 3001, Bulgaria
-
Neurocrine Clinical Site
RECRUITINGBrasov, 500123, Romania
-
Neurocrine Clinical Site
RECRUITINGBrasov, 507190, Romania
-
Neurocrine Clinical Site
RECRUITINGBucharest, 41914, Romania
Conditions
Explore the condition pages connected to this study.